Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on STEM Minnesota.
Press releases published on October 21, 2025
ArcStone Launches New Website for Dream of Wild Health, Latest Recipient of the Unleash the Good Grant
ArcStone launches a new website for Dream of Wild Health, supporting Indigenous food sovereignty through its Unleash the Good Grant initiative. MINNEAPOLIS, MN, UNITED STATES, October 20, 2025 /EINPresswire.com/ -- ArcStone, a Minneapolis-based digital …
Eleva advances CPV-104 into Phase 1b clinical testing in patients with C3G, following the successful completion of single ascending dose evaluation in healthy volunteers
CPV-104 is the only recombinant Factor H in clinical development and has received EU Orphan Drug Designation for C3G Eleva successfully completed the Single Ascending Dose part of the First-in-Human clinical trial evaluating CPV-104 in healthy volunteers …
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
– Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in objective response rate, sustained improvement in desmoid tumor symptoms and consistent safety profile – STAMFORD, Conn., Oct. 21, …
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO® (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
STAMFORD, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that long-term efficacy and safety data from the Phase 3 DeFi trial of OGSIVEO® (nirogacestat), an …
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
Data presented at IDWeek 2025 after study stopped early for efficacy Primary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment1 Data will be shared with regulatory authorities to support regulatory filings …
Galapagos Announces Intention to Wind Down Cell Therapy Business as Part of the Company’s Ongoing Transformation
Intention follows comprehensive strategic review process and would represent the optimal capital allocation pathway to support a stronger and sustainable future for Galapagos Mechelen, Belgium; October 21, 2025, 07:30 CET; regulated information – inside …
Galapagos kondigt intentie aan om celtherapieactiviteiten af te bouwen als onderdeel van de voortdurende transformatie van het bedrijf
Deze intentie volgt na een uitgebreid strategisch evaluatieproces en zou de meest optimale manier zijn om kapitaal toe te wijzen ter ondersteuning van een sterkere en duurzame toekomst voor Galapagos Mechelen, België; 21 oktober 2025, 07:30 CET; …
Utah Company Hawx to Sponsor First-Ever Ski Mountaineering World Cup in the United States
Photo Credit Hawx Smart Pest Control SALT LAKE CITY, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Hawx Smart Pest Control, recently honored as one of the top 50 fastest-growing companies in Utah for 2024 and the state’s fastest-growing pest control brand, announced …
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
WATERTOWN, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious …
BGIN BLOCKCHAIN LIMITED Announces Pricing of Initial Public Offering
SINGAPORE, Oct. 20, 2025 (GLOBE NEWSWIRE) -- BGIN BLOCKCHAIN LIMITED (“BGIN” or “the Company”) (Nasdaq: BGIN), a digital asset technology company with proprietary cryptocurrency-mining technologies, today announced the pricing of its initial public …
XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency
CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and …
Silicone Market worth $33,246.3 million by 2030, at a CAGR of 5.2%, says MarketsandMarkets™
Delray Beach, FL, Oct. 20, 2025 (GLOBE NEWSWIRE) -- The Silicone Market was worth USD 24,502.4 million in 2024 and is projected to reach USD 33,246.3 million by 2030, at a CAGR of 5.2%, as per the recent study by MarketsandMarkets™. Silicone is a high- …